Yüklüyor......
A combination of sorafenib and radiotherapy reduces NF-κB activity and growth of hepatocellular carcinoma in an orthotopic mouse model
Hepatocellular carcinoma (HCC) is difficult to diagnose at an early stage, and its prognosis is generally poor. Sorafenib is the primary treatment for unresectable advanced HCC and targets multiple receptor tyrosine kinases. However, sorafenib only extends the average survival time by 3 months. This...
Kaydedildi:
| Yayımlandı: | Oncol Lett |
|---|---|
| Asıl Yazarlar: | , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
D.A. Spandidos
2021
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7933744/ https://ncbi.nlm.nih.gov/pubmed/33692869 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2021.12598 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|